NEW YORK, March 5 - Ciphergen Biosystems and Beckman Coulter on Tuesday said they plan to automate clinical proteomics research.

Terms of the agreement call for Ciphergen to combine its SELDI protein chip biomarker system with a custom version of Beckman's Biomek 2000 system. The resulting "turnkey" platform will be marketed to industry, academia, and government institutes, the companies said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.